Bausch & Lomb
This article was originally published in The Gray Sheet
Executive Summary
Delaware lower court injunction against U.S. manufacture and sale of PureVision continuous-wear contact lenses is amended to allow distribution of the lenses to participants in the firm's 5,000-patient post-approval study. FDA requires a post-approval study for all manufacturers of 30-day continuous-wear contact lenses; B&L's study commenced in March 2002. The firm reports that it has completed the transfer of PureVision manufacturing from its Rochester, N.Y. plant to Ireland. B&L filed an appeal with the D.C. federal appeals court in June 2002...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.